Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.91 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.91 |
| ▸ | HTT | P42858 | 2/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.91 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.91 |
| ▸ | DRD2 | P14416 | 1/20 | 0.91 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | CNR1 | P21554 | 1/20 | 0.91 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.91 |
| ▸ | HTR2C | P28335 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.91 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.91 |
| ▸ | DRD3 | P35462 | 1/20 | 0.91 |
| ▸ | HTR2B | P41595 | 1/20 | 0.91 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.91 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7324923 | 0.99 | LMNA (0.89) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL29496366 | 0.95 | LMNA (1.00) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL79390 | 0.95 | LMNA (1.00) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL1153647 | 0.94 | LMNA (0.98) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL29439945 | 0.94 | LMNA (0.98) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL404179 | 0.94 | LMNA (0.98) | LMNACHRM2OPRK1HTTADORA3 | |
| Lomerizine SCHEMBL1650277 | 0.93 | LMNA (0.95) | LMNACHRM2OPRK1HTTADORA3 | |
| SCHEMBL7315305 | 0.93 | CHRM2 (0.78) | LMNACHRM2OPRK1HTTADORA3 | |
| Fumaric Acid SCHEMBL7320354 | 0.92 | LMNA (0.77) | LMNACHRM2OPRK1HTTADORA3 | |
| Fumaric Acid SCHEMBL7320343 | 0.92 | LMNA (0.77) | LMNACHRM2OPRK1HTTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0159566-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1985-10-30 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-4663325-A | 1-(2,3,4-tri-methoxybenzyl)-4[bis(4-fluorophenyl)methyl] piperazines are useful for treating cerebrovascular disease | KANEBO LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0159566-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885CHRM2 4828/4885OPRK1 3665/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885CHRM2 4828/4885OPRK1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.